DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells

BACKGROUND: High-grade gliomas are primary brain cancers with unacceptably low and persistent survival rates of 10–16 months for WHO grade 4 gliomas over the last 40 years, despite surgical resection and DNA-damaging chemo-radiotherapy. More recently, tumour-treating fields therapy (TTFields) has de...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderlinden, Aurelie, Jones, Callum G., Myers, Katie N., Rominiyi, Ola, Collis, Spencer J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667536/
https://www.ncbi.nlm.nih.gov/pubmed/37777579
http://dx.doi.org/10.1038/s41416-023-02454-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667536/
https://www.ncbi.nlm.nih.gov/pubmed/37777579
http://dx.doi.org/10.1038/s41416-023-02454-0

Ejemplares similares